Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab

REMD Biotherapeutics

Status and phase

Completed

Phase 1

Conditions

Type 1 Diabetes Mellitus

Treatments

Biological: Volagidemab

Study type

Interventional

Funder types

Industry

Identifiers

NCT06272695

R477-203

Details and patient eligibility

About

This trial is designed to evaluate the effect of glucagon receptor antagonism by volagidemab (once weekly) on glucose recovery from hypoglycemia after treatment with glucagon in adults with type 1 diabetes. After informed consent, Screening procedures to establish subject eligibility will be performed within a period of 28 days. Approximately 24 subjects with type 1 diabetes mellitus (T1DM) on stable doses of insulin will be enrolled.

After enrollment, subjects will undergo a baseline Hypoglycemia Recovery Procedure (with glucagon rescue). Subjects will then receive volagidemab subcutaneously (SC) once weekly for 6 weeks. At the end of the treatment phase, subjects will undergo a second Hypoglycemia Recovery Procedure. Subjects will be followed for 6 weeks after the last volagidemab dose with a final End-of-Study (EOS) visit during Week 12. The primary outcome will be the change in time to glucagon treatment success at Week 6 versus baseline.

Enrollment

24 patients

Sex

All

Ages

18 to 72 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Receiving insulin for the treatment of documented diagnosis of T1DM for at least 2 years
Body Mass Index (BMI) of 18.5 kg/m2 to 35.0 kg/m2
On treatment with a stable insulin regimen for at least 8 weeks
Currently using a continuous glucose monitoring (CGM) system
HbA1c less than or equal to 10.0%
Females of non-childbearing potential must be ≥1 year post-menopausal or documented as being surgically sterile. Females of childbearing potential must agree to use two methods of contraception during the entire study and for an additional 3 months after the end of dosing with the investigational product
Male subjects must be willing to use clinically acceptable method of contraception during the entire study and for an additional 3 months after the end of the treatment period
Other inclusion criteria may apply.

Exclusion criteria

History of type 2 diabetes, maturity onset diabetes of the young (MODY), pancreatic surgery or chronic pancreatitis
Pancreas, pancreatic islet cells, or renal transplant recipient
T1DM treatment with any other antihyperglycemic drug (e.g., metformin, alpha- glucosidase inhibitors, SGLT-2 inhibitors, pramlintide, inhaled insulin, pre-mixed insulins, etc.) within 30 days of Day 1
Occurrence of severe hypoglycemia involving coma and/or seizure that required hospitalization or hypoglycemia-related treatment by an emergency physician or paramedic within 3 months prior to Day 1
Myocardial infarction, unstable angina, revascularization procedure, or cerebrovascular accident ≤12 weeks
Indication of liver disease
Current signs and symptoms of anemia
Untreated eating disorders such as bulimia or anorexia nervosa
History of pancreatitis, pancreatic neuroendocrine tumors or multiple endocrine neoplasia (MEN) or family history of MEN.
Treatment with systemic corticosteroids within 30 days of Day 1, or planned initiation of such therapy during the study.
Medical history of cancer or treatment for cancer in the last five years
Women who are pregnant, nursing, or who plan to become pregnant while in the trial
Other exclusion criteria may apply